Deciphera Pharmaceuticals Inc DCPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DCPH is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
-
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
-
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $14.67
- Day Range
- $14.57–14.84
- 52-Week Range
- $9.90–17.73
- Bid/Ask
- $14.17 / $15.48
- Market Cap
- $1.18 Bil
- Volume/Avg
- 401,815 / 526,681
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 355
- Website
- https://www.deciphera.com
Comparables
Valuation
|
Metric
|
DCPH
|
TYRA
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.35 | 3.45 | 0.78 |
Price/Sales | 7.61 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DCPH
TYRA
VOR
Financial Strength
|
Metric
|
DCPH
|
TYRA
|
VOR
|
|---|---|---|---|
Quick Ratio | 3.37 | 13.27 | 8.81 |
Current Ratio | 3.80 | 13.80 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
DCPH
TYRA
VOR
Profitability
|
Metric
|
DCPH
|
TYRA
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −31.19% | −22.50% | −41.83% |
Return on Equity (Normalized) | −40.38% | −23.73% | −51.69% |
Return on Invested Capital (Normalized) | −40.84% | −27.79% | −47.03% |
Return on Assets
DCPH
TYRA
VOR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Vfvvhhrvf | Cdztks | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Zrnjywjbyc | Ssrmw | $68.3 Bil | |
HLN
| Haleon PLC ADR | Hgzpbyms | Mdn | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Fgbxjgvh | Mqnw | $14.7 Bil | |
VTRS
| Viatris Inc | Zfdvtnrt | Nwm | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Bpfvgdqdr | Yfyr | $11.9 Bil | |
CTLT
| Catalent Inc | Gtpqbbdn | Lylxbt | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Spcljnkl | Nfb | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Jfbtwjxj | Dytbp | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Bccjbfnf | Zkkbrw | $3.5 Bil |